Latest Capital Investment News

Alkane Resources has unveiled its FY2026 production and cost guidance following its merger with Mandalay Resources, projecting significant growth across its Australian and Swedish operations.

New Zealand King Salmon has finalized the purchase of a commercial site in Blenheim, positioning itself for future processing expansion linked to the Blue Endeavour project, while maintaining current operations in Nelson.

DGL Group Limited has issued a corrected FY25 financial presentation, revealing lower EBITDA and NPAT figures due to operational challenges and restructuring costs. Despite revenue growth, the company faces a modified audit opinion on inventory and outlines strategic cost-cutting and growth investments.

Westgold Resources reports a significant 24% increase in gold Mineral Resources to 16.3 million ounces and a 5% rise in Ore Reserves to 3.5 million ounces, underpinning a decade-long Reserve life with robust milling capacity.

OD6 Metals announces a major upgrade at its Splinter Rock Rare Earth Project with the addition of an onsite Chlor-Alkali Facility, promising significant cost savings and enhanced product flexibility. This development could reshape the economics and sustainability profile of one of Australia’s largest rare earth deposits.

Netlinkz Limited has reported a significant 43% reduction in net loss for FY25, driven by a strategic exit from China and Japan and a renewed focus on cybersecurity growth in the Philippines through its Securelink Networks joint venture.

Oldfields Holdings Limited reported a reduced net loss of $3.6 million for FY2025, improving from $7.3 million the previous year, despite ongoing working capital constraints and a costly product recall. The company is actively pursuing capital investment to replenish inventory and support recovery.

Acorn Capital Investment Fund Limited reported a robust FY25 with a $9.67 million profit after tax, a significant leap from $1.77 million the prior year, while delivering a 15.1% portfolio return that outperformed its benchmark.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

AVADA Group Limited reported a revenue decline and a $9.7 million impairment on its New Zealand operations in FY25, while completing Phase 1 of its business transformation including ERP implementation and operational consolidation.

Steamships Trading Company Limited reported a modest 1.7% dip in half-year profit despite a 6.7% rise in revenue, driven by strong divisional performances and significant property gains. The company’s increased capital investment and cautious outlook highlight ongoing challenges and opportunities in Papua New Guinea’s economic landscape.

Powerhouse Ventures Limited reported a striking 348.8% jump in profit after tax to $1.82 million for FY25, driven by strategic acquisitions and a robust investment portfolio. The company’s first operating cash profit and growth in net tangible assets signal a turning point in its transformation.